Skip to main content

Table 3 Surface modification of dental implants with peptides

From: Dental implant bioactive surface modifications and their effects on osseointegration: a review

Author Animal – bone site Surface modification Length of study Findings
Germanier et al. [40] Pig – maxilla 1. SLA (control)
2. SLA + PLL-g-PEG
3. SLA + PLL-g-PEG/PEG-RDG
4. SLA + PLL-g-PEG/PEG-RGD
2 and 4 weeks % of BIC
- SLA: 43.6% at 2 weeks, 62.5% at 4 weeks
- SLA + PLL-g-PEG: 55.9% at 2 weeks, 67.4% at 4 weeks
- SLA + PLL-g-PEG/PEG-RDG: 48.5% at 2 weeks, 75.5% at 4 weeks
- SLA + PLL-g-PEG/PEG-RGD: 61.7% at 2 weeks, 62.5% at 4 weeks
Barros et al. [41] Dog – mandible 1. A: microstructured + HA + low concentrated (20 μg/ml) peptide
2. B: microstructured + HA
3. C: microstructured
4. D: microstructured + HA + high concentrated (200 μg/ml) peptide
12 weeks % of BIC
- A: 60.4%
- B: 62.4%
- C: 58.0%
- D: 65.4%
BD
- A: 54.7%
- B: 46.0%
- C: 45.3%
- D: 40.7%
Yang et al. [42] Rabbit – femur and tibia 1. Control: uncoated
2. RGD-coated
4, 8, and 12 weeks % of BIC
- Control: 50.2%, 58.5%, and 60.9% at 4, 8, and 12 weeks, respectively
- RGD-coated: 70.0%, 74.9%, and 82.2% at 4, 8, and 12 weeks, respectively
Lutz et al. [43] Pig – forehead 1. Group A: HA
2. Group B: HA + P-15 (20 μg/ml)
3. Group C: HA + P-15 (200 μg/ml)
14 and 30 days % of BIC for ROI A and ROI B, respectively
- A: 63.8 & 76.7% at 14 days, 70.9 & 75.8% at 30 days
- B: 72.1 & 72.5% at 14 days, 69.9 & 74.6% at 30 days
- C: 88.2 & 88.7% at 14 days, 80.5 & 88.5% at 30 days
BD for ROI A and ROI B, respectively
- A: 49.5 & 36.2% at 14 days, 38.4 & 28.7% at 30 days
- B: 44.0 & 31.6% at 14 days, 45.7 & 42.9% at 30 days
- C: 44.9 & 36.1% at 14 days, 47.2 & 44.5% at 30 days
Yoo et al. [44] Rabbit - tibia 1. Anodized Ti implant (control)
2. PLGA/rhBMP-2 coated
3 and 7 weeks % of BIC (total)
- Control: 27.26% at 3 weeks; 31.47% at 7 weeks
- PLGA/rhBMP-2: 34.69% at 3 weeks; 35.32% at 7 weeks
  1. SLA sandblasted and acid-etched surface; PLL-g-PEG poly(L-lysine)-graft-poly(ethylene glycol); RDG Arg-Asp-Gly; RGD Arg-Gly-Asp; BIC bone to implant contact; BD bone density; HA hydroxyapatite; P-15 P-15 peptide; ROI region of interest
\